April 27, 2026 5:08pm

And BIG econs later in week

Enjoy the upside, I wave the red flag of caution

As markets balance a tough global risk appetite  

News: Intellia Therapeutics (NTLA closed -0.59 to $13.04 with a -$0.27 after-market) has commenced a $150 M share offering; the usual grant the 30-day option to purchase up to an 15% of the shares of common stock offered in the public offering. Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the proposed offering. <Cash = $449.88 M and debt of -$93.33 M and a BIG Q & FY spend with short % of float ratio of 36.77%>

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions.  I am more frequently right than consequentially wrong; thus, mostly EARLY in my prognostications!

Monday’s RMi Pre-opening: The one sure thing in markets … https://www.regmedinvestors.com/articles/14396

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Monday: The Dow closed DOWN -62.92 points or -0.13%, the S&P closed UP +8.83 points or +0.12% while the Nasdaq closed UP +50.502 points or +0.20%

  • Theme of the session: little changed as Iran peace talks stall and oil rises

Monday (my) 40-company covered sector’s advance/decline line opened positive with 31 incliner, 6 decliners and 3 flats, ending with a positive close of 13 incliners, 24 decliners and 3 flats

  • Sector earnings are coming into view

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Oil prices were higher on Monday as the U.S. and Iran remained in a stalemate. West Texas Intermediate futures rose 2% to above $96 a barrel, while international benchmark Brent oil futures advanced 2% to top $108 per barrel.
  • Traders are also currently pricing in a 100% chance that the Fed will leave rates unchanged at this week’s meeting, with fed funds futures indicating policy is most likely to stay on hold for the rest of the year

The CBOE Fear (VIX) index, Monday closed at 18.02, after Friday’s 18.70, Thursday’s 19.29, Wednesday’s 18.74, Tuesday’s 20.59 and last Monday’s 19.04

Metrics: Monday …

  • The RUT was up +1.19 points or +0.04%,
  • The XLV was down -0.72 points or -0.50%,
  • The NBI was down -26.52 points or -0.45%;
  • The XBI was down -0.24 points or -0.18%
  • The IWM was up +0.49 or +0.18%;
  • The IBB was down -0.76 points or -0.45%,
  • The VIX was down -0.69 points or -3.69% at to 18.02
  • The SPX was up +8,83 or +0.12% to 7,173.91

 

Q2/26 – 1 holiday, 1 neutral, 8 negative and 8 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Monday Closing UP (13 of 13) 

  • Alnylam Pharmaceuticals (ALNY +$2.97 after Friday’s -$8.25),
  • CRISPR Therapeutics (CRSP +$2.21 after Friday’s -$6.40),
  • Beam Therapeutics (BEAM +$2.06 after Friday’s -$3.05),
  • IQVA Holdings (IQV +$1.51 after Friday’s +$1.60),
  • Vericel (VCEL +$1.28 after Friday’s +$1.24),
  • Sarepta Therapeutics (SRPT +$0.68),
  • Lenz Therapeutics (LENZ +$0.38 after Friday’s +$0.23),
  • Entrada Therapeutics (TRDA +$0.33),
  • Agenus (AGEN +$0.19 after Friday’s +$0.14),
  • AxoGen (AXGN +$0.14 after Friday’s +$1.84),
  • Cellectis SA (CLLS +$0.12),
  • BioLife Solutions (BLFS +$0.03),
  • Sangamo Therapeutics (SGMO +$0.0199),

Flat (3)

  • Caribou Biosciences (CRBU)
  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN)

Monday’s Closing DOWN (10 of 24): 

  • Vertex (VRTX -$4.49 after Friday’s -$4.81),
  • BioNTech BNTX -$3.40),
  • Compass Therapeutics (CMPX -$3.23),
  • Moderna (MRNA -$2.03 after Friday’s -$2.12),
  • Ionis Pharmaceuticals (IONS -$1.04 after Friday’s -$0.82),
  • Intellia Therapeutics (NTLA -$0.60 after Friday’s -$2.24),
  • Solid Biosciences (SLDB -$0.42),
  • Arrowhead Pharmaceuticals (ARWR -$0.31 after Friday’s -$0.49),
  • Supernus Therapeutics (SUPN -$0.30 after Friday’s -$0.63),
  • Wave Life Sciences (WVE -$0.24),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

A rally slowed after uncertainty rose about what will/could/would happen next in the Iran war.

What did I write this a.m., “The one sure thing in markets. Is it never stands still; also, beware a later and full week of econs, who take their toll. Stock futures fell as stalled Iran peace talks, an escalation in the Strait of Hormuz pushing oil prices higher, keeping geopolitical tensions front and center heading into an econ laden week>”

The C&GT sector opened positive ending with a deadly dived late afternoon session.

 

April 5th Week:

  • 4/27 - Monday closed negative with 13 incliners, 24 decliners and 3 flats

April 4th Week:

  • 4/24 – Friday closed negative with 11 incliners, 27 decliners and 2 flats
  • 4/23 - Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/22 – Wednesday closed positive with 30 incliners, 9 decliners and 1 flat
  • 4/21 – Tuesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/20 - Monday closed negative with 16 incliners, 21 decliners and 3 flats

 

Q1/26 Earnings Release Dates:

  • AxoGen (AXGN) – Tuesday, 4/28
  • Alnylam Pharmaceuticals (ALNY) -Thursday, 4/30
  • IQVIA Holdings (IQV) and Supernus Therapeutics (SUPN) – Tuesday, 5/5
  • Vericel (VCEL) – Thursday, 5/7

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)
  • Friday: AxoGen (AXGN), IQVA Holdings (IQV) and Capricor Therapeutics (CAPR)
  • Thursday: Alnylam Pharmaceuticals (ALNY), AxoGen (AXGN) and Supernus Therapeutics (SUPN)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR) and Moderna (MRNA)
  • Tuesday: BioNTech (BNTX), Arrowhead Pharmaceuticals (ARWR) and Capricor Therapeutics (CAPR)
  • Last Monday: BioNTech (BNTX), Moderna (MRNA) and BioLife Solutions BLFS)

The worst three (3) in the session: Losers’

  • Monday: Vertex (VRTX), BioNTech (BNTX) and Compass Therapeutics (CMPX)
  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Vertex (VRTX),
  • Thursday: IQVA Holdings (IQV), BioNTech (BNTX) and Vertex (VRTX)
  • Wednesday:  BioNTech (BNTX), IQVA Holdings (IQV) and Mesoblast (MESO)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Last Monday: Vertex (VRTX), AxoGen (AXGN) and Ionis Pharmaceuticals (IONS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.